Martin E Gleave

List of Publications by Year in Descending Order

478 papers	33,404 citations	94 h-index	161 g-index
498 ext. papers	38,679 ext. citations	7.3 avg, IF	6.81 L-index

#	Paper	IF	Citations
478	THEM6-mediated reprogramming of lipid metabolism supports treatment resistance in prostate cancer.. *EMBO Molecular Medicine*, **2022**, e14764	12	2
477	The functions of clusterin in renal mesenchymal stromal cells: Promotion of cell growth and regulation of macrophage activation.. *Experimental Cell Research*, **2022**, 113081	4.2	0
476	Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer. *Nature Communications*, **2021**, 12, 6377	17.4	0
475	SARS-CoV-2 nucleocapsid protein interacts with immunoregulators and stress granules and phase separates to form liquid droplets. *FEBS Letters*, **2021**, 595, 2872	3.8	1
474	Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results From the Canary PASS Cohort. *Journal of Urology*, **2021**, 101097JU0000000000002354	2.5	
473	Development of 2-(5,6,7-Trifluoro-1-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer. *Journal of Medicinal Chemistry*, **2021**, 64, 14968-14982	8.3	2
472	CKB inhibits epithelial-mesenchymal transition and prostate cancer progression by sequestering and inhibiting AKT activation. *Neoplasia*, **2021**, 23, 1147-1165	6.4	1
471	A noncanonical AR addiction drives enzalutamide resistance in prostate cancer. *Nature Communications*, **2021**, 12, 1521	17.4	11
470	Androgen receptor (AR) antagonism triggers acute succinate-mediated adaptive responses to reactivate AR signaling. *EMBO Molecular Medicine*, **2021**, 13, e13427	12	1
469	SLFN5 Regulates LAT1-Mediated mTOR Activation in Castration-Resistant Prostate Cancer. *Cancer Research*, **2021**, 81, 3664-3678	10.1	9
468	Functional mapping of androgen receptor enhancer activity. *Genome Biology*, **2021**, 22, 149	18.3	2
467	Evaluation of Darolutamide (ODM201) Efficiency on Androgen Receptor Mutants Reported to Date in Prostate Cancer Patients. *Cancers*, **2021**, 13,	6.6	3
466	Development of an Androgen Receptor Inhibitor Targeting the N-Terminal Domain of Androgen Receptor for Treatment of Castration Resistant Prostate Cancer. *Cancers*, **2021**, 13,	6.6	2
465	High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 1	8.8	12
464	Integrated Expression of Circulating miR375 and miR371 to Identify Teratoma and Active Germ Cell Malignancy Components in Malignant Germ Cell Tumors. *European Urology*, **2021**, 79, 16-19	10.2	15
463	A polymeric paste-drug formulation for local treatment of upper tract urothelial carcinoma. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 194.e1-194.e7	2.8	0
462	Clusterin regulates macrophage expansion, polarization and phagocytic activity in response to inflammation in the kidneys. *Immunology and Cell Biology*, **2021**, 99, 274-287	5	9

461	Steroidogenesis in Peripheral and Transition Zones of Human Prostate Cancer Tissue. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	1
460	Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies. *Clinical Cancer Research*, **2021**, 27, 2340-2351	12.9	4
459	B2B: Prostate Cancer. *Société Internationale d'Urologie Journal*, **2021**, 2, S30-S50	0.1	
458	An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer. *Nature Cell Biology*, **2021**, 23, 1023-1034	23.4	8
457	Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer. *Cancer*, **2021**,	6.4	1
456	Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer. *JAMA Oncology*, **2021**, 7, 1644-1652	13.4	2
455	The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.. *Nature Communications*, **2021**, 12, 7349	17.4	10
454	Deep Docking: A Deep Learning Platform for Augmentation of Structure Based Drug Discovery. *ACS Central Science*, **2020**, 6, 939-949	16.8	73
453	Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 12315-12323	11.5	28
452	G3BP1-linked mRNA partitioning supports selective protein synthesis in response to oxidative stress. *Nucleic Acids Research*, **2020**, 48, 6855-6873	20.1	14
451	p300-Mediated Acetylation of Histone Demethylase JMJD1A Prevents Its Degradation by Ubiquitin Ligase STUB1 and Enhances Its Activity in Prostate Cancer. *Cancer Research*, **2020**, 80, 3074-3087	10.1	12
450	17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort. *Journal of Clinical Oncology*, **2020**, 38, 1549-1557	2.2	26
449	Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer. *Urologic Oncology: Seminars and Original Investigations*, **2020**, 38, 931.e9-931.e16	2.8	3
448	Design and Characterization of Injectable Poly(Lactic-Co-Glycolic Acid) Pastes for Sustained and Local Drug Release. *Pharmaceutical Research*, **2020**, 37, 36	4.5	9
447	Cancer Cells Employ Nuclear Caspase-8 to Overcome the p53-Dependent G2/M Checkpoint through Cleavage of USP28. *Molecular Cell*, **2020**, 77, 970-984.e7	17.6	10
446	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. *European Urology*, **2020**, 77, 508-547	10.2	155
445	Histone demethylase JMJD1A promotes expression of DNA repair factors and radio-resistance of prostate cancer cells. *Cell Death and Disease*, **2020**, 11, 214	9.8	17
444	Ivermectin inhibits HSP27 and potentiates efficacy of oncogene targeting in tumor models. *Journal of Clinical Investigation*, **2020**, 130, 699-714	15.9	14

443	LIN28B promotes the development of neuroendocrine prostate cancer. *Journal of Clinical Investigation*, **2020**, 130, 5338-5348	15.9	23
442	Chemotherapeutic Agents for Urologic Oncology: Basic Principles **2020**, 611-637		
441	Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer. *European Urology*, **2020**, 78, 834-844	10.2	23
440	African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study. *Journal of Urology*, **2020**, 203, 727-733	2.5	20
439	Magnetic Resonance Imaging for the Detection of High Grade Cancer in the Canary Prostate Active Surveillance Study. *Journal of Urology*, **2020**, 204, 701-706	2.5	9
438	Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma. *Clinical Genitourinary Cancer*, **2020**, 18, 322-331.e2	3.3	14
437	Transient Sox9 Expression Facilitates Resistance to Androgen-Targeted Therapy in Prostate Cancer. *Clinical Cancer Research*, **2020**, 26, 1678-1689	12.9	11
436	A polymeric paste-drug formulation for intratumoral treatment of prostate cancer. *Prostate Cancer and Prostatic Diseases*, **2020**, 23, 324-332	6.2	3
435	Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer. *Prostate Cancer and Prostatic Diseases*, **2020**, 23, 316-323	6.2	3
434	Improving prostate cancer classification in H&E tissue micro arrays using Ki67 and P63 histopathology. *Computers in Biology and Medicine*, **2020**, 127, 104053	7	1
433	The DNA methylation landscape of advanced prostate cancer. *Nature Genetics*, **2020**, 52, 778-789	36.3	71
432	Clusterin Deficiency Predisposes C57BL/6j Mice to Cationic Bovine Serum Albumin-Induced Glomerular Inflammation. *Journal of Inflammation Research*, **2020**, 13, 969-983	4.8	0
431	Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer. *Clinical Cancer Research*, **2020**, 26, 4616-4624	12.9	4
430	Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer. *PLoS ONE*, **2020**, 15, e0237248	3.7	5
429	Paternally Expressed Gene 10 (PEG10) Promotes Growth, Invasion, and Survival of Bladder Cancer. *Molecular Cancer Therapeutics*, **2020**, 19, 2210-2220	6.1	5
428	Autoantibody Landscape in Patients with Advanced Prostate Cancer. *Clinical Cancer Research*, **2020**, 26, 6204-6214	12.9	4
427	Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability. *JAMA Oncology*, **2020**, 6, e203187	13.4	14
426	The molecular function of kallikrein-related peptidase 14 demonstrates a key modulatory role in advanced prostate cancer. *Molecular Oncology*, **2020**, 14, 105-128	7.9	10

425	Predicting complications following radical cystectomy with the ACS NSQIP universal surgical risk calculator. *World Journal of Urology*, **2020**, 38, 1215-1220	4	7
424	Discovery of New Catalytic Topoisomerase II Inhibitors for Anticancer Therapeutics. *Frontiers in Oncology*, **2020**, 10, 633142	5.3	5
423	Re: Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE). *European Urology*, **2019**, 75, 692-693	10.2	
422	Abi1 loss drives prostate tumorigenesis through activation of EMT and non-canonical WNT signaling. *Cell Communication and Signaling*, **2019**, 17, 120	7.5	17
421	Developing a Highly Specific Biomarker for Germ Cell Malignancies: Plasma miR371 Expression Across the Germ Cell Malignancy Spectrum. *Journal of Clinical Oncology*, **2019**, 37, 3090-3098	2.2	44
420	Towards precision oncology in advanced prostate cancer. *Nature Reviews Urology*, **2019**, 16, 645-654	5.5	72
419	Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS). *Prostate Cancer and Prostatic Diseases*, **2019**, 22, 438-445	6.2	12
418	ONECUT2 is a driver of neuroendocrine prostate cancer. *Nature Communications*, **2019**, 10, 278	17.4	72
417	Reply to Rodolfo Montironi, Liang Cheng, Marina Scarpelli, Alessia Cimadamore, Francesco Montorsi, and Antonio Lopez-Beltrán's Letter to the Editor re: Gillian Vandekerkhove, Werner J. Struss, Matti Annala, et al. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. Eur Urol 2019;75:667-75. How Does Circulating DNA Reach the Blood	10.2	
416	A Prospective Study on F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer. *Journal of Nuclear Medicine*, **2019**, 60, 1587-1593	8.9	49
415	RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression. *European Urology*, **2019**, 76, 157-166	10.2	12
414	Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity. *Molecular Cancer Research*, **2019**, 17, 1235-1240	6.6	30
413	Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. *European Urology*, **2019**, 76, 562-571	10.2	49
412	MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. *Prostate Cancer and Prostatic Diseases*, **2019**, 22, 531-538	6.2	32
411	GnRH Antagonists Have Direct Inhibitory Effects On Castration-Resistant Prostate Cancer Via Intracrine Androgen and AR-V7 Expression. *Molecular Cancer Therapeutics*, **2019**, 18, 1811-1821	6.1	7
410	2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC). *Canadian Urological Association Journal*, **2019**, 13, 307-314	1.2	9
409	Validation of the prognostic value of NF-B p65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker Network. *PLoS Medicine* , **2019**, 16, e1002847	11.6	15
408	Stress-induced tunneling nanotubes support treatment adaptation in prostate cancer. *Scientific Reports*, **2019**, 9, 7826	4.9	25

407	The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer. *EMBO Molecular Medicine*, **2019**, 11, e10659	12	37
406	Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. *Lancet Oncology, The*, **2019**, 20, 1730-1739	21.7	126
405	Continued 5-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS. *Journal of Urology*, **2019**, 201, 106-111	2.5	3
404	BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma. *Genome Medicine*, **2019**, 11, 8	14.4	52
403	Identification and characterization of small molecule inhibitors of the ubiquitin ligases Siah1/2 in melanoma and prostate cancer cells. *Cancer Letters*, **2019**, 449, 145-162	9.9	8
402	Class I HDAC inhibitors enhance YB-1 acetylation and oxidative stress to block sarcoma metastasis. *EMBO Reports*, **2019**, 20, e48375	6.5	44
401	Characterization of a Prostate- and Prostate Cancer-Specific Circular RNA Encoded by the Androgen Receptor Gene. *Molecular Therapy - Nucleic Acids*, **2019**, 18, 916-926	10.7	21
400	SRRM4 gene expression correlates with neuroendocrine prostate cancer. *Prostate*, **2019**, 79, 96-104	4.2	16
399	A molecular portrait of epithelial-mesenchymal plasticity in prostate cancer associated with clinical outcome. *Oncogene*, **2019**, 38, 913-934	9.2	46
398	Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial. *European Urology*, **2019**, 75, 940-947	10.2	41
397	Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. *European Urology*, **2019**, 75, 667-675	10.2	74
396	Subtle Protective Roles of Clusterin in Gastric Metaplasia After Acute Oxyntic Atrophy. *Cellular and Molecular Gastroenterology and Hepatology*, **2019**, 7, 246-250.e1	7.9	1
395	Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer. *Clinical Cancer Research*, **2019**, 25, 710-723	12.9	8
394	Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer. *European Urology*, **2019**, 75, 44-60	10.2	29
393	A Multi-Institutional Validation of Gleason Score Derived from Tissue Microarray Cores. *Pathology and Oncology Research*, **2019**, 25, 979-986	2.6	2
392	The impact of time to metastasis on overall survival in patients with prostate cancer. *World Journal of Urology*, **2018**, 36, 1039-1046	4	18
391	Heterochromatin Protein 1 Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer. *Cancer Research*, **2018**, 78, 2691-2704	10.1	31
390	HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis. *Nature Communications*, **2018**, 9, 1431	17.4	13

389	Clinical and molecular features of treatment-related neuroendocrine prostate cancer. *International Journal of Urology*, **2018**, 25, 345-351	2.3	71
388	Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study. *European Urology*, **2018**, 73, 706-712	10.2	11
387	Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes. *European Urology*, **2018**, 74, 211-217	10.2	22
386	Aneustat (OMN54) has aerobic glycolysis-inhibitory activity and also immunomodulatory activity as indicated by a first-generation PDX prostate cancer model. *International Journal of Cancer*, **2018**, 143, 419-429	7.5	5
385	Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer. *Cancer Discovery*, **2018**, 8, 444-457	24.4	247
384	SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1. *EMBO Molecular Medicine*, **2018**, 10, 219-238	12	25
383	A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer. *Investigational New Drugs*, **2018**, 36, 278-287	4.3	25
382	Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. *European Urology*, **2018**, 73, 715-723	10.2	71
381	Histone demethylase JMJD1A promotes alternative splicing of AR variant 7 (AR-V7) in prostate cancer cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E4584-E4593	11.5	53
380	Molecular model for neuroendocrine prostate cancer progression. *BJU International*, **2018**, 122, 560-570	5.6	30
379	Co-targeting driver pathways in prostate cancer: two birds with one stone. *EMBO Molecular Medicine*, **2018**, 10,	12	5
378	Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer. *European Urology*, **2018**, 73, 949-960	10.2	9
377	Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer. *European Urology*, **2018**, 73, 524-532	10.2	35
376	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. *European Urology*, **2018**, 73, 178-211	10.2	313
375	Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201). *European Urology*, **2018**, 73, 4-8	10.2	50
374	Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. *Cell*, **2018**, 174, 758-769.e9	56.2	234
373	Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease. *Carcinogenesis*, **2018**, 39, 1431-1437	4.6	26
372	Targeting MCT4 to reduce lactic acid secretion and glycolysis for treatment of neuroendocrine prostate cancer. *Cancer Medicine*, **2018**, 7, 3385	4.8	30

371	Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancer. *Oncotarget*, **2018**, 9, 6550-6561	3.3	13
370	Long term deficiency of vitamin D in germ cell testicular cancer survivors. *Oncotarget*, **2018**, 9, 21078-21085	3.3	2
369	Natural history of prostatic lesions on serial multiparametric magnetic resonance imaging. *Canadian Urological Association Journal*, **2018**, 12, 270-275	1.2	5
368	A prospective randomized pilot study evaluating an ERAS protocol versus a standard protocol for patients treated with radical cystectomy and urinary diversion for bladder cancer. *World Journal of Urology*, **2018**, 36, 215-220	4	47
367	Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. *Journal of Clinical Oncology*, **2018**, 36, 2492-2503	2.2	271
366	Loss of Nuclear Functions of HOXA10 Is Associated With Testicular Cancer Proliferation. *Frontiers in Oncology*, **2018**, 8, 594	5.3	7
365	Targeting Semaphorin 3C in Prostate Cancer With Small Molecules. *Journal of the Endocrine Society*, **2018**, 2, 1381-1394	0.4	6
364	The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation. *BMC Urology*, **2018**, 18, 78	2.2	6
363	Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB-EZH2-TSP1 pathway in prostate cancers. *Nature Communications*, **2018**, 9, 4080	17.4	78
362	Characterization of Precursor-Dependent Steroidogenesis in Human Prostate Cancer Models. *Cancers*, **2018**, 10,	6.6	6
361	Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer. *European Journal of Medicinal Chemistry*, **2018**, 160, 108-119	6.8	24
360	The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications. *GigaScience*, **2018**, 7,	7.6	35
359	Natural history of prostatic lesions on serial multiparametric magnetic resonance imaging. *Canadian Urological Association Journal*, **2018**,	1.2	7
358	SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition. *European Urology*, **2017**, 71, 68-78	10.2	105
357	Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study. *Journal of Urology*, **2017**, 197, 1026-1033	2.5	10
356	Re: Robotic versus Open Prostatectomy: End of the Controversy: M. O. Koch J Urol 2016;196:9-10. *Journal of Urology*, **2017**, 197, 820-821	2.5	
355	Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality. *Oncogene*, **2017**, 36, 3417-3427	8.2	47
354	Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial. *Lancet Oncology, The*, **2017**, 18, 473-485	21.7	58

353	Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer. *European Urology*, **2017**, 72, 34-42	10.2	127
352	Neoadjuvant Enzalutamide Prior to Prostatectomy. *Clinical Cancer Research*, **2017**, 23, 2169-2176	12.9	50
351	Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study. *European Urology*, **2017**, 72, 448-454	10.2	49
350	Clonality Inference from Single Tumor Samples Using Low-Coverage Sequence Data. *Journal of Computational Biology*, **2017**, 24, 515-523	1.7	16
349	Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI. *European Journal of Nuclear Medicine and Molecular Imaging*, **2017**, 44, 776-787	8.8	95
348	Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer. *Canadian Urological Association Journal*, **2017**, 11, 16-23	1.2	12
347	Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer. *Canadian Urological Association Journal*, **2017**, 11, E62-E63	1.2	
346	Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. *Journal of Clinical Oncology*, **2017**, 35, 3097-3104	2.2	215
345	Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy. *Clinical Cancer Research*, **2017**, 23, 6802-6811	12.9	50
344	Semaphorin 3 C drives epithelial-to-mesenchymal transition, invasiveness, and stem-like characteristics in prostate cells. *Scientific Reports*, **2017**, 7, 11501	4.9	20
343	Identifying intermediate-risk candidates for active surveillance of prostate cancer. *Urologic Oncology: Seminars and Original Investigations*, **2017**, 35, 605.e1-605.e8	2.8	13
342	Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor-Chromatin Interactions. *Molecular Cancer Therapeutics*, **2017**, 16, 2281-2291	6.1	16
341	Quantification of large scale DNA organization for predicting prostate cancer recurrence. *Cytometry Part A: the Journal of the International Society for Analytical Cytology*, **2017**, 91, 1164-1174	4.6	8
340	A germline FANCA alteration that is associated with increased sensitivity to DNA damaging agents. *Journal of Physical Education and Sports Management*, **2017**, 3,	2.8	15
339	Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	182
338	A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy. *Clinical Cancer Research*, **2017**, 23, 1974-1980	12.9	25
337	Suppression of LIM and SH3 Domain Protein 1 (LASP1) Negatively Regulated by Androgen Receptor Delays Castration Resistant Prostate Cancer Progression. *Prostate*, **2017**, 77, 309-320	4.2	6
336	The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer. *Cancer Discovery*, **2017**, 7, 54-71	24.4	173

335	Effect of Targeting Clusterin Using OGX-011 on Antitumor Activity of Temsirolimus in a Human Renal Cell Carcinoma Model. *Targeted Oncology*, **2017**, 12, 69-79	5	1
334	Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer. *Clinical Cancer Research*, **2017**, 23, 1542-1551	12.9	17
333	AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate. *Journal of Urology*, **2017**, 197, 135-142	2.5	90
332	Assessment of quality of life (QOL), cognitive function and depression in a randomized phase II study of abiraterone acetate (ABI) plus prednisone (P) vs enzalutamide (ENZA) for metastatic castrate-resistant prostate cancer (mCRPC).. *Journal of Clinical Oncology*, **2017**, 35, 5036-5036	2.2	4
331	Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapy. *PLoS ONE*, **2017**, 12, e0172048	3.7	15
330	Androgen receptor transcriptionally regulates semaphorin 3C in a GATA2-dependent manner. *Oncotarget*, **2017**, 8, 9617-9633	3.3	13
329	Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance. *Oncotarget*, **2017**, 8, 18949-18967	3.3	38
328	Metabolic heterogeneity signature of primary treatment-naïve prostate cancer. *Oncotarget*, **2017**, 8, 25928-25941	3.3	12
327	Alternative RNA splicing of the MEAF6 gene facilitates neuroendocrine prostate cancer progression. *Oncotarget*, **2017**, 8, 27966-27975	3.3	24
326	Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer. *Oncotarget*, **2017**, 8, 42438-42454	3.3	28
325	Establishment of a neuroendocrine prostate cancer model driven by the RNA splicing factor SRRM4. *Oncotarget*, **2017**, 8, 66878-66888	3.3	16
324	Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. *Journal of Urology*, **2016**, 195, 313-20	2.5	93
323	Regulation of c-Myc expression by the histone demethylase JMJD1A is essential for prostate cancer cell growth and survival. *Oncogene*, **2016**, 35, 2441-52	9.2	75
322	Testosterone Therapy Can be Given to Men with No Concern that it will Promote Prostate Cancer Development or Progression: Con. *Journal of Urology*, **2016**, 196, 985-8	2.5	6
321	Discovery of a Metastatic Immune Escape Mechanism Initiated by the Loss of Expression of the Tumour Biomarker Interleukin-33. *Scientific Reports*, **2016**, 6, 30555	4.9	37
320	Cheminformatics Modeling of Adverse Drug Responses by Clinically Relevant Mutants of Human Androgen Receptor. *Journal of Chemical Information and Modeling*, **2016**, 56, 2507-2516	6.1	11
319	Transcriptome-Based Analysis of Molecular Pathways for Clusterin Functions in Kidney Cells. *Journal of Cellular Physiology*, **2016**, 231, 2628-38	7	10
318	PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer. *European Urology Focus*, **2016**, 2, 180-188	5.1	52

317	Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives. *European Urology*, **2016**, 69, 775-87	10.2	52
316	Integrated analysis of the prostate cancer small-nucleolar transcriptome reveals SNORA55 as a driver of prostate cancer progression. *Molecular Oncology*, **2016**, 10, 693-703	7.9	33
315	The MCT4 Gene: A Novel, Potential Target for Therapy of Advanced Prostate Cancer. *Clinical Cancer Research*, **2016**, 22, 2721-33	12.9	57
314	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy*, **2016**, 12, 1-222	10.2	3838
313	Moving Toward Personalized Care: Liquid Biopsy Predicts Response to Cisplatin in an Unusual Case of BRCA2-Null Neuroendocrine Prostate Cancer. *Clinical Genitourinary Cancer*, **2016**, 14, e233-6	3.3	12
312	Targeting Cancer Stem Cells in Castration-Resistant Prostate Cancer. *Clinical Cancer Research*, **2016**, 22, 670-9	12.9	60
311	Effects of abiraterone (ABI) and enzalutamide (ENZA) on cognitive impairment and depressive symptoms in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. *Journal of Clinical Oncology*, **2016**, 34, 5059-5059	2.2	4
310	MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study. *PLoS ONE*, **2016**, 11, e0165236	3.7	19
309	Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor. *Oncotarget*, **2016**, 7, 40690-40703	3.3	11
308	Loss of Expression of AZGP1 Is Associated With Worse Clinical Outcomes in a Multi-Institutional Radical Prostatectomy Cohort. *Prostate*, **2016**, 76, 1409-19	4.2	17
307	Relationship of clusterin with renal inflammation and fibrosis after the recovery phase of ischemia-reperfusion injury. *BMC Nephrology*, **2016**, 17, 133	2.7	28
306	Clusterin knockdown sensitizes prostate cancer cells to taxane by modulating mitosis. *EMBO Molecular Medicine*, **2016**, 8, 761-78	12	23
305	Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized: Analysis of the Relative Prognostic Strength of Individual Architectural Patterns in 1275 Patients From the Canary Retrospective Cohort. *American Journal of Surgical Pathology*, **2016**, 40, 1439-1456	6.7	79
304	Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundation-Supported West Coast Prostate Cancer Dream Team. *European Urology Focus*, **2016**, 2, 469-471	5.1	9
303	Requirement of clusterin expression for prosurvival autophagy in hypoxic kidney tubular epithelial cells. *American Journal of Physiology - Renal Physiology*, **2016**, 310, F160-73	4.3	23
302	Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients. *Genome Biology*, **2016**, 17, 10	18.3	124
301	A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers. *Annals of Oncology*, **2016**, 27, 1116-1122	10.3	58
300	Clonality Inference from Single Tumor Samples Using Low Coverage Sequence Data. *Lecture Notes in Computer Science*, **2016**, 83-94	0.9	8

299	Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer. *JAMA Oncology*, **2016**, 2, 1598-1606	13.4	226
298	Prognostic value of Ki67 in localized prostate carcinoma: a multi-institutional study of >1000 prostatectomies. *Prostate Cancer and Prostatic Diseases*, **2016**, 19, 264-70	6.2	36
297	Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH. *Modern Pathology*, **2016**, 29, 904-14	9.8	61
296	UGT2B17 Expedites Progression of Castration-Resistant Prostate Cancers by Promoting Ligand-Independent AR Signaling. *Cancer Research*, **2016**, 76, 6701-6711	10.1	27
295	Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth. *Clinical Cancer Research*, **2015**, 21, 1675-87	12.9	90
294	The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors. *International Journal of Cancer*, **2015**, 136, E27-38	7.5	61
293	Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. *Annals of Oncology*, **2015**, 26, 1589-604	10.3	220
292	Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary-Early Detection Research Network Active Surveillance Biopsy Risk Calculator. *European Urology*, **2015**, 68, 1083-8	10.2	39
291	Multiparametric magnetic resonance imaging-targeted biopsy for the detection of prostate cancer in patients with prior negative biopsy results. *Urologic Oncology: Seminars and Original Investigations*, **2015**, 33, 165.e1-7	2.8	27
290	Targeting the adaptive molecular landscape of castration-resistant prostate cancer. *EMBO Molecular Medicine*, **2015**, 7, 878-94	12	83
289	YB-1 regulates stress granule formation and tumor progression by translationally activating G3BP1. *Journal of Cell Biology*, **2015**, 208, 913-29	7.3	154
288	Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer. *Clinical Cancer Research*, **2015**, 21, 2315-24	12.9	334
287	siRNA Lipid Nanoparticle Potently Silences Clusterin and Delays Progression When Combined with Androgen Receptor Cotargeting in Enzalutamide-Resistant Prostate Cancer. *Clinical Cancer Research*, **2015**, 21, 4845-55	12.9	46
286	The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer. *Cell Reports*, **2015**, 12, 922-36	10.6	155
285	Targeting heat shock proteins in metastatic castration-resistant prostate cancer. *Nature Reviews Urology*, **2015**, 12, 26-36	5.5	69
284	Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies. *European Urology*, **2015**, 68, 228-35	10.2	127
283	Anticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancer. *Molecular Cancer Therapeutics*, **2015**, 14, 59-69	6.1	72
282	Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models. *European Urology*, **2015**, 67, 986-990	10.2	70

281	Hsp27 regulates EGF/β-catenin mediated epithelial to mesenchymal transition in prostate cancer. *International Journal of Cancer*, **2015**, 136, E496-507	7.5	47
280	Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development. *Journal of Pathology*, **2015**, 236, 278-89	9.4	208
279	Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis. *Scientific Reports*, **2015**, 5, 15182	4.9	24
278	Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma. *Neoplasia*, **2015**, 17, 805-16	6.4	14
277	Progesterone receptor expression during prostate cancer progression suggests a role of this receptor in stromal cell differentiation. *Prostate*, **2015**, 75, 1043-50	4.2	28
276	Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients. *PLoS ONE*, **2015**, 10, e0132343	3.7	25
275	Clusterin Seals the Ocular Surface Barrier in Mouse Dry Eye. *PLoS ONE*, **2015**, 10, e0138958	3.7	20
274	Large oncosomes contain distinct protein cargo and represent a separate functional class of tumor-derived extracellular vesicles. *Oncotarget*, **2015**, 6, 11327-41	3.3	214
273	Hsp27 Inhibition with OGX-427 Sensitizes Non-Small Cell Lung Cancer Cells to Erlotinib and Chemotherapy. *Molecular Cancer Therapeutics*, **2015**, 14, 1107-16	6.1	34
272	Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. *JAMA Oncology*, **2015**, 1, 466-74	13.4	207
271	A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer. *Prostate*, **2015**, 75, 1206-15	4.2	47
270	The Steroidogenic Enzyme AKR1C3 Regulates Stability of the Ubiquitin Ligase Siah2 in Prostate Cancer Cells. *Journal of Biological Chemistry*, **2015**, 290, 20865-20879	5.4	22
269	Multiparametric magnetic resonance imaging enhances detection of significant tumor in patients on active surveillance for prostate cancer. *Urology*, **2015**, 85, 423-8	1.6	43
268	Targeting Integrin-Linked Kinase Suppresses Invasion and Metastasis through Downregulation of Epithelial-to-Mesenchymal Transition in Renal Cell Carcinoma. *Molecular Cancer Therapeutics*, **2015**, 14, 1024-34	6.1	23
267	Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancer. *Oncotarget*, **2015**, 6, 1806-20	3.3	33
266	Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer. *Oncotarget*, **2015**, 6, 9086-98	3.3	31
265	Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts. *Oncotarget*, **2015**, 6, 14318-28	3.3	37
264	Catalytic inhibitors of DNA topoisomerase II suppress the androgen receptor signaling and prostate cancer progression. *Oncotarget*, **2015**, 6, 20474-84	3.3	16

263	Downregulation of c-SRC kinase CSK promotes castration resistant prostate cancer and pinpoints a novel disease subclass. *Oncotarget*, **2015**, 6, 22060-71	3.3	4
262	Inhibition of endoplasmic reticulum chaperone protein glucose-regulated protein 78 potentiates anti-angiogenic therapy in renal cell carcinoma through inactivation of the PERK/eIF2 pathway. *Oncotarget*, **2015**, 6, 34818-30	3.3	11
261	AR-v7 protein expression is regulated by protein kinase and phosphatase. *Oncotarget*, **2015**, 6, 33743-54	3.3	32
260	A Novel Triazole Nucleoside Suppresses Prostate Cancer Cell Growth by Inhibiting Heat Shock Factor 1 and Androgen Receptor. *Anti-Cancer Agents in Medicinal Chemistry*, **2015**, 15, 1333-40	2.2	12
259	Canadian guidelines for the management of small renal masses (SRM). *Canadian Urological Association Journal*, **2015**, 9, 160-3	1.2	36
258	A 2D-3D Registration Framework for Freehand TRUS-Guided Prostate Biopsy. *Lecture Notes in Computer Science*, **2015**, 272-279	0.9	6
257	The Melbourne Consensus Statement on the early detection of prostate cancer. *BJU International*, **2014**, 113, 186-8	5.6	50
256	Insulin-like growth factor-I induces CLU expression through Twist1 to promote prostate cancer growth. *Molecular and Cellular Endocrinology*, **2014**, 384, 117-25	4.4	10
255	The tyrphostin NT157 suppresses insulin receptor substrates and augments therapeutic response of prostate cancer. *Molecular Cancer Therapeutics*, **2014**, 13, 2827-39	6.1	30
254	Reproducibility and efficiency of serum-derived exosome extraction methods. *Clinical Biochemistry*, **2014**, 47, 1286-92	3.5	159
253	MP31-09 IDENTIFICATION OF A RETRO-TRANSPOSON DERIVED GENE ASSOCIATED WITH PROGRESSION TO NEUROENDOCRINE PROSTATE CANCER.. *Journal of Urology*, **2014**, 191,	2.5	3
252	Motion and deformation compensation for freehand prostate biopsies **2014**,		1
251	Prostate stromal cells express the progesterone receptor to control cancer cell mobility. *PLoS ONE*, **2014**, 9, e92714	3.7	27
250	Good servants, poor masters. *Canadian Urological Association Journal*, **2014**, 8, 163	1.2	
249	Comparison of open and robotic-assisted prostatectomy: The University of British Columbia experience. *Canadian Urological Association Journal*, **2014**, 8, 92-7	1.2	19
248	Aggressive variants of castration-resistant prostate cancer. *Clinical Cancer Research*, **2014**, 20, 2846-50	12.9	245
247	High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. *Cancer Research*, **2014**, 74, 1272-83	10.1	250
246	Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer. *Genome Biology*, **2014**, 15, 426	18.3	57

245	Next-generation steroidogenesis inhibitors, dutasteride and abiraterone, attenuate but still do not eliminate androgen biosynthesis in 22RV1 cells in vitro. *Journal of Steroid Biochemistry and Molecular Biology*, **2014**, 144 Pt B, 436-44	5.1	11
244	Promotion of cell proliferation by clusterin in the renal tissue repair phase after ischemia-reperfusion injury. *American Journal of Physiology - Renal Physiology*, **2014**, 306, F724-33	4.3	42
243	Crosstalk between nuclear MET and SOX9/β-catenin correlates with castration-resistant prostate cancer. *Molecular Endocrinology*, **2014**, 28, 1629-39		31
242	Clusterin facilitates stress-induced lipidation of LC3 and autophagosome biogenesis to enhance cancer cell survival. *Nature Communications*, **2014**, 5, 5775	17.4	76
241	The role of DAB2IP in androgen receptor activation during prostate cancer progression. *Oncogene*, **2014**, 33, 1954-63	9.2	40
240	Growth kinetics of small renal masses: A prospective analysis from the Renal Cell Carcinoma Consortium of Canada. *Canadian Urological Association Journal*, **2014**, 8, 24-7	1.2	38
239	Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 4251-6	11.5	94
238	Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer. *European Urology*, **2014**, 66, 145-55	10.2	59
237	Castration-resistant prostate cancer: from new pathophysiology to new treatment. *European Urology*, **2014**, 65, 289-99	10.2	94
236	Systematic identification and characterization of RNA editing in prostate tumors. *PLoS ONE*, **2014**, 9, e101431	3.7	14
235	GATA2 as a potential metastasis-driving gene in prostate cancer. *Oncotarget*, **2014**, 5, 451-61	3.3	49
234	The role of homeostatic regulation between tumor suppressor DAB2IP and oncogenic Skp2 in prostate cancer growth. *Oncotarget*, **2014**, 5, 6425-36	3.3	33
233	The BIRC6 gene as a novel target for therapy of prostate cancer: dual targeting of inhibitors of apoptosis. *Oncotarget*, **2014**, 5, 6896-908	3.3	24
232	Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma. *Oncotarget*, **2014**, 5, 7805-19	3.3	20
231	Co-targeting Adaptive Survival Pathways. *Current Clinical Urology*, **2014**, 233-248		
230	GRP78 regulates clusterin stability, retrotranslocation and mitochondrial localization under ER stress in prostate cancer. *Oncogene*, **2013**, 32, 1933-42	9.2	80
229	Radical prostatectomy in high-risk prostate cancer. *International Journal of Urology*, **2013**, 20, 290-300	2.3	16
228	Extracellular HSP27 mediates angiogenesis through Toll-like receptor 3. *FASEB Journal*, **2013**, 27, 4169-83	5.9	80

227	Protein expression of PTEN, insulin-like growth factor I receptor (IGF-IR), and lethal prostate cancer: a prospective study. *Cancer Epidemiology Biomarkers and Prevention*, **2013**, 22, 1984-93	4	37
226	Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo. *Molecular Cancer Therapeutics*, **2013**, 12, 2342-55	6.1	98
225	Cotargeting Androgen Receptor and Clusterin Delays Castrate-Resistant Prostate Cancer Progression by Inhibiting Adaptive Stress Response and AR Stability. *Cancer Research*, **2013**, 73, 5206-17	10.1	55
224	The mechanism of DAB2IP in chemoresistance of prostate cancer cells. *Clinical Cancer Research*, **2013**, 19, 4740-9	12.9	52
223	Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. *Clinical Cancer Research*, **2013**, 19, 2442-50	12.9	117
222	TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling. *International Journal of Cancer*, **2013**, 133, 1955-66	7.5	37
221	Mutation of the salt bridge-forming residues in the ETV6-SAM domain interface blocks ETV6-NTRK3-induced cellular transformation. *Journal of Biological Chemistry*, **2013**, 288, 27940-50	5.4	12
220	Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancer. *Cancer Research*, **2013**, 73, 3109-19	10.1	149
219	Hiding in plain view: genetic profiling reveals decades old cross contamination of bladder cancer cell line KU7 with HeLa. *Journal of Urology*, **2013**, 190, 1404-9	2.5	24
218	The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity. *Cancer Cell*, **2013**, 23, 332-46	24.3	107
217	IGF2 increases de novo steroidogenesis in prostate cancer cells. *Endocrine-Related Cancer*, **2013**, 20, 173-86	3.7	36
216	Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer. *Asian Journal of Andrology*, **2013**, 15, 342-9	2.8	23
215	The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. *Cell*, **2013**, 153, 1064-79	56.2	276
214	Expression and role of the angiotensin II AT2 receptor in human prostate tissue: in search of a new therapeutic option for prostate cancer. *Prostate*, **2013**, 73, 1057-68	4.2	22
213	Molecular Mechanisms of Castrate Resistant Prostate Cancer **2013**, 43-64		
212	Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. *Journal of Clinical Oncology*, **2013**, 31, 1740-7	2.2	159
211	Plasma miRNAs as biomarkers to identify patients with castration-resistant metastatic prostate cancer. *International Journal of Molecular Sciences*, **2013**, 14, 7757-70	6.3	98
210	A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue Microarray. *Advances in Anatomic Pathology*, **2013**, 20, 39-44	5.1	15

209	Expression and function of the progesterone receptor in human prostate stroma provide novel insights to cell proliferation control. *Journal of Clinical Endocrinology and Metabolism*, **2013**, 98, 2887-96	5.6	62
208	The promise of heat shock protein inhibitors in the treatment of castration resistant prostate cancer. *Current Opinion in Urology*, **2013**, 23, 194-200	2.8	27
207	A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo. *Molecular Cancer Therapeutics*, **2013**, 12, 567-76	6.1	78
206	Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsen. *Cancer Medicine*, **2013**, 2, 468-77	4.8	17
205	Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer. *Prostate Cancer and Prostatic Diseases*, **2013**, 16, 187-92	6.2	51
204	Blocked autophagy using lysosomotropic agents sensitizes resistant prostate tumor cells to the novel Akt inhibitor AZD5363. *Clinical Cancer Research*, **2013**, 19, 833-44	12.9	74
203	Targeting amino acid transport in metastatic castration-resistant prostate cancer: effects on cell cycle, cell growth, and tumor development. *Journal of the National Cancer Institute*, **2013**, 105, 1463-73	9.7	119
202	Inhibition of HSP27 blocks fibrosis development and EMT features by promoting Snail degradation. *FASEB Journal*, **2013**, 27, 1549-60	0.9	77
201	BIRC6 protein, an inhibitor of apoptosis: role in survival of human prostate cancer cells. *PLoS ONE*, **2013**, 8, e55837	3.7	22
200	Novel non-AR therapeutic targets in castrate resistant prostate cancer. *Translational Andrology and Urology*, **2013**, 2, 265-77	2.3	4
199	Clusterin as a Target for Treatment of Castration-Resistant Prostate Cancer **2013**, 329-340		
198	Tissue uptake of docetaxel loaded hydrophobically derivatized hyperbranched polyglycerols and their effects on the morphology of the bladder urothelium. *Biomaterials*, **2012**, 33, 692-703	15.6	26
197	Decrease in donor heart injury by recombinant clusterin protein in cold preservation with University of Wisconsin solution. *Surgery*, **2012**, 151, 364-71	3.6	11
196	Underestimation of Gleason score at prostate biopsy reflects sampling error in lower volume tumours. *BJU International*, **2012**, 109, 660-4	5.6	59
195	The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume. *BJU International*, **2012**, 110, 36-42	5.6	48
194	Positive surgical margins are a risk factor for significant biochemical recurrence only in intermediate-risk disease. *BJU International*, **2012**, 110, 821-7	5.6	21
193	The importance of integrin-linked kinase in the regulation of bladder cancer invasion. *International Journal of Cancer*, **2012**, 130, 521-31	7.5	45
192	Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer. *Journal of Thoracic Oncology*, **2012**, 7, 579-86	8.9	60

191	Targeted therapies in metastatic castration-resistant prostate cancer: beyond the androgen receptor. *Urologic Clinics of North America*, **2012**, 39, 517-31	2.9	13
190	Hsp27 silencing coordinately inhibits proliferation and promotes Fas-induced apoptosis by regulating the PEA-15 molecular switch. *Cell Death and Differentiation*, **2012**, 19, 990-1002	12.7	41
189	Clusterin mediates TGF-□induced epithelial-mesenchymal transition and metastasis via Twist1 in prostate cancer cells. *Cancer Research*, **2012**, 72, 5261-72	10.1	116
188	Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer. *Journal of Urology*, **2012**, 188, 103-9	2.5	40
187	The 16p13.3 (PDPK1) Genomic Gain in Prostate Cancer: A Potential Role in Disease Progression. *Translational Oncology*, **2012**, 5, 453-60	4.9	23
186	Validation of a sequential extraction and liquid chromatography-tandem mass spectrometric method for determination of dihydrotestosterone, androstanediol and androstanediol-glucuronide in prostate tissues. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2012**, 902, 84-95	3.2	12
185	Apo J/clusterin expression and secretion: evidence for 15-deoxy-□12,14)-PGJ(2)-dependent mechanism. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2012**, 1821, 335-42	5	2
184	Small heat shock proteins in cancer therapy and prognosis. *International Journal of Biochemistry and Cell Biology*, **2012**, 44, 1646-56	5.6	130
183	Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. *Cancer Research*, **2012**, 72, 1878-89	10.1	354
182	Poly-gene fusion transcripts and chromothripsis in prostate cancer. *Genes Chromosomes and Cancer*, **2012**, 51, 1144-53	5	39
181	Identification of CD166 as a surface marker for enriching prostate stem/progenitor and cancer initiating cells. *PLoS ONE*, **2012**, 7, e42564	3.7	76
180	TP53INP1 overexpression in prostate cancer correlates with poor prognostic factors and is predictive of biological cancer relapse. *Prostate*, **2012**, 72, 117-28	4.2	17
179	Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors. *Prostate*, **2012**, 72, 875-85	4.2	7
178	TP53INP1 as new therapeutic target in castration-resistant prostate cancer. *Prostate*, **2012**, 72, 1286-94	4.2	10
177	Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer. *Journal of Pathology*, **2012**, 227, 53-61	9.4	51
176	From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. *Journal of Pathology*, **2012**, 227, 286-97	9.4	142
175	Carbidopa abrogates L-dopa decarboxylase coactivation of the androgen receptor and delays prostate tumor progression. *International Journal of Cancer*, **2012**, 130, 2835-44	7.5	15
174	Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. *Cancer*, **2012**, 118, 5709-18	6.4	82

173	Targeted therapy in prostate cancer. *Histopathology*, **2012**, 60, 216-31	7.3	14
172	Next-generation sequencing of prostate tumors provides independent evidence of xenotropic murine leukemia virus-related gammaretrovirus contamination. *Journal of Clinical Microbiology*, **2012**, 50, 536-7	9.7	2
171	Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target. *Molecular Cancer Therapeutics*, **2012**, 11, 775-83	6.1	30
170	Expression and function of myometrial PSF suggest a role in progesterone withdrawal and the initiation of labor. *Molecular Endocrinology*, **2012**, 26, 1370-9		24
169	A phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancer. *Clinical Cancer Research*, **2012**, 18, 3407-13	12.9	41
168	Cotargeting stress-activated Hsp27 and autophagy as a combinatorial strategy to amplify endoplasmic reticular stress in prostate cancer. *Molecular Cancer Therapeutics*, **2012**, 11, 1661-71	6.1	45
167	Slug, a unique androgen-regulated transcription factor, coordinates androgen receptor to facilitate castration resistance in prostate cancer. *Molecular Endocrinology*, **2012**, 26, 1496-507		41
166	Targeting TCTP as a new therapeutic strategy in castration-resistant prostate cancer. *Molecular Therapy*, **2012**, 20, 2244-56	11.7	52
165	Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. *Cancer Discovery*, **2011**, 1, 487-95	24.4	550
164	Reduction of cold ischemia-reperfusion injury by graft-expressing clusterin in heart transplantation. *Journal of Heart and Lung Transplantation*, **2011**, 30, 819-26	5.8	18
163	Targeting the androgen receptor--theory and practice. *Urology*, **2011**, 78, S482-4	1.6	5
162	Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists. *Journal of Medicinal Chemistry*, **2011**, 54, 7693-704	8.3	42
161	MicroRNAs associated with metastatic prostate cancer. *PLoS ONE*, **2011**, 6, e24950	3.7	163
160	Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence. *BJU International*, **2011**, 108, E202-10	5.6	83
159	The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. *EMBO Journal*, **2011**, 30, 2719-33	13	423
158	Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. *European Urology*, **2011**, 60, 205-10	10.2	140
157	Active surveillance of small renal masses: progression patterns of early stage kidney cancer. *European Urology*, **2011**, 60, 39-44	10.2	339
156	New therapies for castration-resistant prostate cancer: efficacy and safety. *European Urology*, **2011**, 60, 279-90	10.2	111

155	Human prostate cancer xenografts in lit/lit mice exhibit reduced growth and androgen-independent progression. *Prostate*, **2011**, 71, 525-37	4.2	17
154	Use of irinotecan for treatment of small cell carcinoma of the prostate. *Prostate*, **2011**, 71, 675-81	4.2	21
153	OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer. *Cell Death and Disease*, **2011**, 2, e221	9.8	66
152	In vitro and in vivo evaluation of intravesical docetaxel loaded hydrophobically derivatized hyperbranched polyglycerols in an orthotopic model of bladder cancer. *Biomacromolecules*, **2011**, 12, 949-60	6.9	24
151	Consensus PP1 binding motifs regulate transcriptional corepression and alternative RNA splicing activities of the steroid receptor coregulators, p54nrb and PSF. *Molecular Endocrinology*, **2011**, 25, 1197-210		18
150	Clusterin is a critical downstream mediator of stress-induced YB-1 transactivation in prostate cancer. *Molecular Cancer Research*, **2011**, 9, 1755-66	6.6	52
149	Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer. *Cancer Research*, **2011**, 71, 5838-49	10.1	72
148	Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. *Clinical Cancer Research*, **2011**, 17, 5765-73	12.9	110
147	Transcription factor Stat5 knockdown enhances androgen receptor degradation and delays castration-resistant prostate cancer progression in vivo. *Molecular Cancer Therapeutics*, **2011**, 10, 347-59	6.1	48
146	Progression from high-grade prostatic intraepithelial neoplasia to cancer: a randomized trial of combination vitamin-E, soy, and selenium. *Journal of Clinical Oncology*, **2011**, 29, 2386-90	2.2	54
145	Insulin increases de novo steroidogenesis in prostate cancer cells. *Cancer Research*, **2011**, 71, 5754-64	10.1	80
144	In vivo evaluation of mucoadhesive nanoparticulate docetaxel for intravesical treatment of non-muscle-invasive bladder cancer. *Clinical Cancer Research*, **2011**, 17, 2788-98	12.9	45
143	A novel HSP90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis. *Clinical Cancer Research*, **2011**, 17, 2301-13	12.9	46
142	Radical prostatectomy for high-risk clinically localized prostate cancer: a prospective single institution series. *Canadian Urological Association Journal*, **2011**, 5, E156-61	1.2	7
141	Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. *Nature Medicine*, **2010**, 16, 1414-20	50.5	248
140	Molecular decoy to the Y-box binding protein-1 suppresses the growth of breast and prostate cancer cells whilst sparing normal cell viability. *PLoS ONE*, **2010**, 5, e12661	3.7	37
139	Hsp27 promotes insulin-like growth factor-I survival signaling in prostate cancer via p90Rsk-dependent phosphorylation and inactivation of BAD. *Cancer Research*, **2010**, 70, 2307-17	10.1	63
138	Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. *Clinical Cancer Research*, **2010**, 16, 1088-93	12.9	111

137	Clusterin facilitates COMMD1 and I-kappaB degradation to enhance NF-kappaB activity in prostate cancer cells. *Molecular Cancer Research*, **2010**, 8, 119-30	6.6	104
136	Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. *Journal of Clinical Oncology*, **2010**, 28, 4247-54	2.2	195
135	Novel targeted agents on the horizon for castration-resistant prostate cancer. *Future Oncology*, **2010**, 6, 1883-95	3.6	4
134	Expression of receptors for luteinizing hormone-releasing hormone (LH-RH) in prostate cancers following therapy with LH-RH agonists. *Clinical Cancer Research*, **2010**, 16, 4675-80	12.9	39
133	Loss of clusterin expression worsens renal ischemia-reperfusion injury. *American Journal of Physiology - Renal Physiology*, **2010**, 298, F568-78	4.3	43
132	Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository. *Urology*, **2010**, 75, 407-13	1.6	48
131	Words of wisdom. Re: comparative effectiveness of minimally invasive versus open radical prostatectomy. *European Urology*, **2010**, 57, 1118-9	10.2	
130	Antisense oligonucleotide targeting of insulin-like growth factor-1 receptor (IGF-1R) in prostate cancer. *Prostate*, **2010**, 70, 206-18	4.2	31
129	Arachidonic acid activation of intratumoral steroid synthesis during prostate cancer progression to castration resistance. *Prostate*, **2010**, 70, 239-51	4.2	41
128	Inhibition of DHCR24/seladin-1 impairs cellular homeostasis in prostate cancer. *Prostate*, **2010**, 70, 921-33	4.2	15
127	Cell Biology of Prostate Cancer and Molecular Targets **2010**, 1-24		
126	In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors. *Clinical Cancer Research*, **2009**, 15, 39-47	12.9	115
125	Heat shock protein 27 as a new therapeutic target for radiation sensitization of head and neck squamous cell carcinoma. *Molecular Therapy*, **2009**, 17, 1387-94	11.7	52
124	PTEN loss promotes mitochondrially dependent type II Fas-induced apoptosis via PEA-15. *Molecular and Cellular Biology*, **2009**, 29, 1222-34	4.8	36
123	Intravesical combination treatment with antisense oligonucleotides targeting heat shock protein-27 and HTI-286 as a novel strategy for high-grade bladder cancer. *Molecular Cancer Therapeutics*, **2009**, 8, 2402-11	6.1	37
122	PAMAM dendrimers mediate siRNA delivery to target Hsp27 and produce potent antiproliferative effects on prostate cancer cells. *ChemMedChem*, **2009**, 4, 1302-10	3.7	102
121	Insulin receptor expression by human prostate cancers. *Prostate*, **2009**, 69, 33-40	4.2	165
120	Chemosensitization of gemcitabine-resistant human bladder cancer cell line both in vitro and in vivo using antisense oligonucleotide targeting the anti-apoptotic gene, clusterin. *BJU International*, **2009**, 103, 384-90	5.6	28

119	Paclitaxel incorporated in hydrophobically derivatized hyperbranched polyglycerols for intravesical bladder cancer therapy. *BJU International*, **2009**, 103, 978-86	5.6	67
118	Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors. *European Journal of Cancer*, **2009**, 45, 1846-54	7.5	37
117	The continued debate: intermittent vs. continuous hormonal ablation for metastatic prostate cancer. *Urologic Oncology: Seminars and Original Investigations*, **2009**, 27, 81-6	2.8	25
116	Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts. *Journal of Steroid Biochemistry and Molecular Biology*, **2009**, 115, 126-36	5.1	42
115	Paclitaxel and cisplatin as intravesical agents against non-muscle-invasive bladder cancer. *BJU International*, **2008**, 101, 1347-55	5.6	36
114	Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. *BJU International*, **2008**, 102, 389-97	5.6	104
113	Intravesically administered antisense oligonucleotides targeting heat-shock protein-27 inhibit the growth of non-muscle-invasive bladder cancer. *BJU International*, **2008**, 102, 610-6	5.6	42
112	Evaluation of novel bifunctional chelates for the development of Cu-64-based radiopharmaceuticals. *Nuclear Medicine and Biology*, **2008**, 35, 875-82	2.1	47
111	Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. *Journal of Urology*, **2008**, 180, 565-70; discussion 570	2.5	97
110	Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer. *Expert Opinion on Investigational Drugs*, **2008**, 17, 1955-62	5.9	35
109	Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. *Cancer Research*, **2008**, 68, 6407-15	10.1	595
108	GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer. *Clinical Cancer Research*, **2008**, 14, 5769-77	12.9	52
107	The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells. *Journal of Biological Chemistry*, **2008**, 283, 3349-3356	5.4	147
106	A phase I study of OGX-011, a 2Pmethoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. *Clinical Cancer Research*, **2008**, 14, 833-9	12.9	105
105	Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer. *Clinical Cancer Research*, **2008**, 14, 6944-54	12.9	65
104	Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer. *Cancer Research*, **2008**, 68, 4506-10	10.1	42
103	ASAP1, a gene at 8q24, is associated with prostate cancer metastasis. *Cancer Research*, **2008**, 68, 4352-9	10.1	73
102	Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin. *International Journal of Cancer*, **2008**, 122, 2368-76	7.5	26

101	Clusterin antisense complexed with chitosan for controlled intratumoral delivery. *International Journal of Pharmaceutics*, **2008**, 350, 53-64	6.5	19
100	DJ-1 binds androgen receptor directly and mediates its activity in hormonally treated prostate cancer cells. *Cancer Research*, **2007**, 67, 4630-7	10.1	81
99	Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells. *Molecular Cancer Therapeutics*, **2007**, 6, 299-308	6.1	153
98	A validated mouse model for orthotopic bladder cancer using transurethral tumour inoculation and bioluminescence imaging. *BJU International*, **2007**, 100, 1377-84	5.6	57
97	Therapeutic options in advanced prostate cancer: present and future. *Current Urology Reports*, **2007** , 8, 53-9	2.9	18
96	Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. *Cancer Research*, **2007**, 67, 10455-65	10.1	197
95	Differential regulation of clusterin and its isoforms by androgens in prostate cells. *Journal of Biological Chemistry*, **2007**, 282, 2278-87	5.4	57
94	Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. *Cancer Research*, **2007**, 67, 5033-41	10.1	420
93	The role of stress proteins in prostate cancer. *Current Genomics*, **2007**, 8, 252-61	2.6	33
92	Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 16170-5	11.5	459
91	Standard treatments induce antigen-specific immune responses in prostate cancer. *Clinical Cancer Research*, **2007**, 13, 1493-502	12.9	134
90	Novel targets and approaches in advanced prostate cancer. *Current Opinion in Urology*, **2007**, 17, 182-7	2.8	22
89	Comparing a generic and individualized information decision support intervention for men newly diagnosed with localized prostate cancer. *Cancer Nursing*, **2007**, 30, E7-15	2.6	59
88	Therapeutic options for hormone-refractory prostate cancer in 2007. *Urologic Oncology: Seminars and Original Investigations*, **2007**, 25, 413-9	2.8	52
87	Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors. *Human Pathology*, **2007**, 38, 161-70	3.7	31
86	Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. *Journal of Clinical Oncology*, **2007**, 25, 1196-208	2.2	172
85	NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. *Cancer Cell*, **2006**, 9, 367-78	24.3	138
84	Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: clinical parameters. *Cancer*, **2006**, 107, 389-95	6.4	78

83	Cyclin G-associated kinase: a novel androgen receptor-interacting transcriptional coactivator that is overexpressed in hormone refractory prostate cancer. *International Journal of Cancer*, **2006**, 118, 1108-19	7.5	45
82	Inhibition of the phosphatidylinositol 3Pkinase pathway promotes autocrine Fas-induced death of phosphatase and tensin homologue-deficient prostate cancer cells. *Cancer Research*, **2006**, 66, 4781-8	10.1	37
81	The insulin-like growth factor I receptor is required for Akt activation and suppression of anoikis in cells transformed by the ETV6-NTRK3 chimeric tyrosine kinase. *Molecular and Cellular Biology*, **2006** , 26, 1754-69	4.8	63
80	Expression and nuclear localization of ErbB3 in prostate cancer. *Clinical Cancer Research*, **2006**, 12, 2730-7	12.9	99
79	Expression of clusterin in prostate cancer correlates with Gleason score but not with prognosis in patients undergoing radical prostatectomy without neoadjuvant hormonal therapy. *Urology*, **2006**, 68, 609-14	1.6	31
78	Loss of PTEN is associated with progression to androgen independence. *Prostate*, **2006**, 66, 895-902	4.2	67
77	Relaxin becomes upregulated during prostate cancer progression to androgen independence and is negatively regulated by androgens. *Prostate*, **2006**, 66, 1698-709	4.2	41
76	Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes. *BJU International*, **2006**, 97, 1300-8	5.6	54
75	Small interference RNA targeting heat-shock protein 27 inhibits the growth of prostatic cell lines and induces apoptosis via caspase-3 activation in vitro. *BJU International*, **2006**, 98, 1082-9	5.6	103
74	Loss of functional E-cadherin renders cells more resistant to the apoptotic agent taxol in vitro. *Experimental Cell Research*, **2005**, 310, 99-104	4.2	46
73	Therapeutic efficacy of adenoviral-mediated p53 gene transfer is synergistically enhanced by combined use of antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. *Neoplasia*, **2005**, 7, 171-9	6.4	26
72	Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. *Cancer Research*, **2005**, 65, 11083-93	10.1	181
71	A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells. *Molecular Cancer Therapeutics*, **2005**, 4, 1689-98	6.1	92
70	Clusterin as a therapeutic target for radiation sensitization in a lung cancer model. *International Journal of Radiation Oncology Biology Physics*, **2005**, 63, 1228-36	4	29
69	Knock-down of the cytoprotective gene, clusterin, to enhance hormone and chemosensitivity in prostate and other cancers. *Annals of the New York Academy of Sciences*, **2005**, 1058, 1-15	6.5	36
68	Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic. *International Journal of Urology*, **2005**, 12, 785-94	2.3	45
67	Antisense therapy for cancer. *Nature Reviews Cancer*, **2005**, 5, 468-79	31.3	290
66	Clusterin regulates drug-resistance in melanoma cells. *Journal of Investigative Dermatology*, **2005**, 124, 1300-7	4.3	38

65	Antisense clusterin oligodeoxynucleotides increase the response of HER-2 gene amplified breast cancer cells to Trastuzumab. *Journal of Cellular Physiology*, **2005**, 204, 463-9	7	33
64	Efficacy of an intratumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel or docetaxel in prostate cancer xenograft models. *Cancer Chemotherapy and Pharmacology*, **2005**, 56, 239-47	3.5	31
63	Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer. *Cancer Chemotherapy and Pharmacology*, **2005**, 56 Suppl 1, 47-57	3.5	36
62	Mechanisms of the development of androgen independence in prostate cancer. *World Journal of Urology*, **2005**, 23, 1-9	4	129
61	Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer. *World Journal of Urology*, **2005**, 23, 38-46	4	84
60	The inhibition of angiogenesis by antisense oligonucleotides to clusterin. *Angiogenesis*, **2005**, 8, 229-38	10.6	29
59	Intake of selenium in the prevention of prostate cancer: a systematic review and meta-analysis. *Cancer Causes and Control*, **2005**, 16, 1125-31	2.8	114
58	A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2Pmethoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. *Journal of the National Cancer Institute*, **2005**, 97, 1287-96	9.7	248
57	Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer. *Clinical Cancer Research*, **2005**, 11, 4905-11	12.9	51
56	Antisense oligodeoxynucleotide therapy for bladder cancer: recent advances and future prospects. *Expert Review of Anticancer Therapy*, **2005**, 5, 1001-9	3.5	7
55	Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo. *Molecular Cancer Therapeutics*, **2005**, 4, 1837-49	6.1	77
54	High-risk localized prostate cancer: a case for early chemotherapy. *Journal of Clinical Oncology*, **2005**, 23, 8186-91	2.2	28
53	A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. *Clinical Cancer Research*, **2005**, 11, 3854-61	12.9	156
52	Synergistic antitumor effect of combined use of adenoviral-mediated p53 gene transfer and antisense oligodeoxynucleotide targeting clusterin gene in an androgen-independent human prostate cancer model. *Molecular Cancer Therapeutics*, **2005**, 4, 187-95	6.1	11
51	Enhanced radiosensitivity by inhibition of the anti-apoptotic gene clusterin using antisense oligodeoxynucleotide in a human bladder cancer model. *Oncology Reports*, **2005**, 13, 885-90	3.5	12
50	Enhanced expression of the secreted form of clusterin following neoadjuvant hormonal therapy as a prognostic predictor in patients undergoing radical prostatectomy for prostate cancer. *Oncology Reports*, **2005**, 14, 1371-5	3.5	29
49	Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. *Cancer Research*, **2004**, 64, 6595-602	10.1	254
48	Silencing expression of the clusterin/apolipoprotein j gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress. *Cancer Research*, **2004**, 64, 1834-42	10.1	186

47	Protein profiling of microdissected prostate tissue links growth differentiation factor 15 to prostate carcinogenesis. *Cancer Research*, **2004**, 64, 5929-33	10.1	83
46	Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. *Cancer Research*, **2004**, 64, 8620-9	10.1	138
45	Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. *Cancer Research*, **2004**, 64, 2212-21	10.1	220
44	Regulation of tumor angiogenesis by integrin-linked kinase (ILK). *Cancer Cell*, **2004**, 5, 79-90	24.3	226
43	YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity. *Prostate*, **2004**, 59, 337-49	4.2	130
42	Protection of androgen-dependent human prostate cancer cells from oxidative stress-induced DNA damage by overexpression of clusterin and its modulation by androgen. *Prostate*, **2004**, 61, 318-23	4.2	67
41	Synergistic antitumor activity by combined treatment with gemcitabine and antisense oligodeoxynucleotide targeting clusterin gene in an intravesical administration model against human bladder cancer kotcc-1 cells. *Journal of Urology*, **2004**, 171, 2477-81	2.5	36
40	Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. *Molecular Cancer Therapeutics*, **2004**, 3, 223-32	6.1	76
39	Clusterin and IGFBPs as antisense targets in prostate cancer. *Annals of the New York Academy of Sciences*, **2003**, 1002, 95-104	6.5	36
38	Androgens and prostate cancer. *World Journal of Urology*, **2003**, 21, 325-37	4	32
37	Antisense targets to enhance hormone and cytotoxic therapies in advanced prostate cancer. *Current Drug Targets*, **2003**, 4, 209-21	3	25
36	Resistance to cytotoxic chemotherapy-induced apoptosis in human prostate cancer cells is associated with intracellular clusterin expression. *Oncology Reports*, **2003**, 10, 469-73	3.5	33
35	Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. *Cancer Research*, **2003**, 63, 3575-84	10.1	78
34	Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. *Prostate*, **2002**, 50, 179-88	4.2	193
33	Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer. *Investigational New Drugs*, **2002**, 20, 145-58	4.3	23
32	Antisense therapy: current status in prostate cancer and other malignancies. *Cancer and Metastasis Reviews*, **2002**, 21, 79-92	9.6	32
31	Assessing information and decision preferences of men with prostate cancer and their partners. *Cancer Nursing*, **2002**, 25, 42-9	2.6	177
30	Overexpression of clusterin in transitional cell carcinoma of the bladder is related to disease progression and recurrence. *Urology*, **2002**, 59, 150-4	1.6	87

29	Introducing the Clusterin Gene Into Human Renal Cell Carcinoma Cells Enhances Their Metastatic Potential. *Journal of Urology*, **2002**, 167, 2203-2208	2.5	46
28	Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. *Clinical Cancer Research*, **2002**, 8, 3276-84	12.9	104
27	Novel therapeutic strategy for advanced prostate cancer using antisense oligodeoxynucleotides targeting anti-apoptotic genes upregulated after androgen withdrawal to delay androgen-independent progression and enhance chemosensitivity. *International Journal of Urology*, **2001**, 8, 337-49	2.3	30
26	Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model. *International Journal of Cancer*, **2001**, 91, 846-50	7.5	84
25	Introduction of clusterin gene into human renal cell carcinoma cells enhances their resistance to cytotoxic chemotherapy through inhibition of apoptosis both in vitro and in vivo. *Japanese Journal of Cancer Research*, **2001**, 92, 1220-4		35
24	Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer. *Urology*, **2001**, 58, 39-49	1.6	73
23	Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. *Neoplasia*, **2001**, 3, 360-7	6.4	96
22	RANDOMIZED COMPARATIVE STUDY OF 3 VERSUS 8-MONTH NEOADJUVANT HORMONAL THERAPY BEFORE RADICAL PROSTATECTOMY: BIOCHEMICAL AND PATHOLOGICAL EFFECTS. *Journal of Urology*, **2001**, 166, 500-507	2.5	227
21	Acquisition of resistance to Fas-mediated apoptosis by overexpression of clusterin in human renal-cell carcinoma cells. *Molecular Urology*, **2001**, 5, 105-11		39
20	Inhibition of progression to androgen-independence by combined adjuvant treatment with antisense BCL-XL and antisense Bcl-2 oligonucleotides plus taxol after castration in the Shionogi tumor model. *International Journal of Cancer*, **2000**, 86, 855-62	7.5	57
19	Polymeric micellar paclitaxel phosphorylates Bcl-2 and induces apoptotic regression of androgen-independent LNCaP prostate tumors. *Prostate*, **2000**, 44, 156-63	4.2	52
18	Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides. *Journal of the National Cancer Institute*, **2000**, 92, 34-41	9.7	161
17	Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3Pkinase pathway. *Endocrinology*, **2000**, 141, 2257-65	4.8	125
16	Long-term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up. *Urology*, **2000**, 56, 289-94	1.6	47
15	Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides. *Urology*, **1999**, 54, 36-46	1.6	90
14	Differential transactivation by the androgen receptor in prostate cancer cells. *Prostate*, **1998**, 36, 256-63	4.2	32
13	Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model **1998**, 69, 271-281		23
12	Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. *New England Journal of Medicine*, **1998**, 338, 1265-71	59.2	245

11	Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c-Jun in the human prostate cancer cell line LNCaP. *Journal of Biological Chemistry*, **1997**, 272, 17485-94	5.4	153
10	Biochemical and Pathological Effects of 8 Months of Neoadjuvant Androgen Withdrawal Therapy Before Radical Prostatectomy in Patients with Clinically Confined Prostate Cancer. *Journal of Urology*, **1996**, 155, 213-219	2.5	140
9	Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. *Journal of Steroid Biochemistry and Molecular Biology*, **1996**, 58, 139-46	5.1	164
8	Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer. *Urology*, **1996**, 47, 708-12	1.6	104
7	Control of tumor progression by maintenance of apoptosis. *Prostate*, **1996**, 29, 13-21	4.2	30
6	Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy. The case for primary retroperitoneal lymph node dissection of stage IIb germ cell tumors with teratomatous elements. *Cancer*, **1996**, 78, 480-6	6.4	17
5	Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. *Urology*, **1995**, 45, 839-44; discussion 844-5	1.6	257
4	Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. *International Journal of Cancer*, **1994**, 57, 406-12	7.5	384
3	Human prostate cancer model: roles of growth factors and extracellular matrices. *Journal of Cellular Biochemistry*, **1992**, 16H, 99-105	4.7	76
2	Neonatal renomegaly. *Journal of Urology*, **1987**, 138, 1023-7	2.5	20
1	Dynamic phase separation of the androgen receptor and its coactivators to regulate gene expression		3